eMedicine Specialties > Emergency Medicine > Toxicology

Plant Poisoning, Caladium, Dieffenbachia, and Philodendron

Author: Jennifer S Boyle, MD, PharmD, Fellow in Toxicology, University of Virginia Health System
Coauthor(s): Christopher P Holstege, MD, Associate Professor of Emergency Medicine and Pediatrics, University of Virginia; Director, Division of Medical Toxicology, Center of Clinical Toxicology; Medical Director, Blue Ridge Poison Ctr, Associate Medical Toxicology Fellowship Director, VA Dept of Health
Contributor Information and Disclosures

Updated: Dec 9, 2008

Introduction

Background

According to the 2006 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System, 2,403,539 human exposures were reported, of which 64,236 (2.7%) were exposures to plants.1 Children younger than 5 years were responsible for 44,710 of those plant exposures.1 The plant species most frequently reported in human exposures were Spathiphyllum, Euphorbia pulcherrima, and Ilex. Philodendron and Caladium species were also listed among the most commonly reported plant exposures. Philodendron and Dieffenbachia species (also called dumb cane) are commonly found in homes, offices, and waiting rooms.

Philodendron.

Philodendron.

Philodendron.

Philodendron.


Dieffenbachia.

Dieffenbachia.

Dieffenbachia.

Dieffenbachia.


Pathophysiology

Philodendron, Dieffenbachia, and Caladium contain calcium oxalate crystals packaged into bundles called raphides. However, the presence of calcium oxalate crystals alone is not enough to cause the toxicity seen with exposure to these plants. Although the exact mechanism of toxicity remains unclear, the presence of proteolytic enzymes, in addition to specialized cells that forcibly expel the raphides, seems to be necessary to inflict injury.

Caladium.

Caladium.

Caladium.

Caladium.


Split leaf philodendron.

Split leaf philodendron.

Split leaf philodendron.

Split leaf philodendron.


Frequency

United States

In 2006, data collected by the American Association of Poison Control Centers indicated that plants were the 16th most commonly reported substance involved in human toxic exposures.1 Children younger than 5 years were responsible for most of these exposures.

Mortality/Morbidity

Patients with history of oral exposure (chewing and/or swallowing) have been reported to have severe swelling, drooling, dysphagia, and respiratory compromise, but this is not common. In a large retrospective study of 188 patients with plant oxalate exposure, all cases were determined to be minor and all resolved with minor or no treatment. Patients can also experience dermal and ocular exposure, resulting in contact dermatitis or keratoconjunctivitis. Symptoms that result from these routes of exposure also appear to resolve with supportive care. The serious complication of aortoesophageal fistula following ingestion of a dieffenbachia leaf in a girl aged 12.5 years has been described in a single 2005 case report.2 The girl recovered following surgical intervention.

Age

In patients with exposure to toxic plants, 70% are children younger than 5 years.

Clinical

History

In patients with exposure to Caladium, Dieffenbachia, or Philodendron , assess the usual important features associated with toxic environmental exposure, namely, identification of the substance, time and duration of exposure, symptomatology, treatment thus far, associated injuries, and preexisting conditions.

  • Identification: If possible, ask the parents to bring in a sample of the plant. Plants often are known by various names, both common and scientific. Identification of the plant is greatly aided by the presence of the plant or a portion of it.
  • Time and duration of exposure: Inquire about the level of exposure, including the amount and time of exposure.
  • Symptomatology: Patients usually develop immediate burning and irritation of the oral mucosa, which generally deters any further exposure.
  • Prior treatment: Patients may have been instructed to try demulcifying agents (eg, cold milk, ice cream) or may have taken analgesics prior to presentation.
  • Associated injuries
    • Inquire about any other potential exposures or injury. Often, more than one plant is present in the immediate vicinity.
    • Children also may have fallen or bitten their lips in association with the pain or swelling.
  • Preexisting conditions: Inquire about past medical history, medications, and allergies.

Physical

  • Assess airway patency; however, swelling severe enough to cause airway compromise is extremely uncommon. Breathing and circulation are usually unaffected.
  • Children who chew the leaves develop immediate burning and irritation of the oral mucosa, which may be red and edematous. Many children exhibit mild transient drooling. Severe swelling, drooling, dysphagia, and respiratory compromise have been reported but are not common.
  • Cutaneous exposure can cause redness and irritation but is not nearly as common as oral exposure caused by chewing.
  • Ocular exposure may result in eye pain, redness, and lid swelling.

More on Plant Poisoning, Caladium, Dieffenbachia, and Philodendron

Overview: Plant Poisoning, Caladium, Dieffenbachia, and Philodendron
Differential Diagnoses & Workup: Plant Poisoning, Caladium, Dieffenbachia, and Philodendron
Treatment & Medication: Plant Poisoning, Caladium, Dieffenbachia, and Philodendron
Follow-up: Plant Poisoning, Caladium, Dieffenbachia, and Philodendron
Multimedia: Plant Poisoning, Caladium, Dieffenbachia, and Philodendron
References

References

  1. Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila). Dec 2007;45(8):815-917. [Medline].

  2. Snajdauf J, Mixa V, Rygl M, Vyhnanek M, Moravek J, Kabelka Z. Aortoesophageal fistula--an unusual complication of esophagitis caused by Dieffenbachia ingestion. J Pediatr Surg. Jun 2005;40(6):e29-31. [Medline].

  3. Arditti J, Rodriguez E. Dieffenbachia: uses, abuses and toxic constituents: a review. J Ethnopharmacol. May 1982;5(3):293-302. [Medline].

  4. Cumpston KL, Vogel SN, Leikin JB, Erickson TB. Acute airway compromise after brief exposure to a Dieffenbachia plant. J Emerg Med. Nov 2003;25(4):391-7. [Medline].

  5. Evans CR. Oral ulceration after contact with the houseplant Dieffenbachia. Br Dent J. Jun 20 1987;162(12):467-8. [Medline].

  6. Gardner DG. Injury to the oral mucous membranes caused by the common houseplant, dieffenbachia. A review. Oral Surg Oral Med Oral Pathol. Nov 1994;78(5):631-3. [Medline].

  7. Krenzelok EP, Jacobsen TD. Plant exposures ... a national profile of the most common plant genera. Vet Hum Toxicol. Aug 1997;39(4):248-9. [Medline].

  8. Kuballa B, Lugnier AA, Anton R. Study of Dieffenbachia-induced edma in mouse and rat hindpaw: respective role of oxalate needles an trypsin-like protease. Toxicol Appl Pharmacol. May 1981;58(3):444-51. [Medline].

  9. Lawrence RA. Poisonous plants: when they are a threat to children. Pediatr Rev. May 1997;18(5):162-8. [Medline].

  10. Mrvos R, Dean BS, Krenzelok EP. Philodendron/dieffenbachia ingestions: are they a problem?. J Toxicol Clin Toxicol. 1991;29(4):485-91. [Medline].

  11. Pedaci L, Krenzelok EP, Jacobsen TD, Aronis J. Dieffenbachia species exposures: an evidence-based assessment of symptom presentation. Vet Hum Toxicol. Oct 1999;41(5):335-8. [Medline].

  12. Rao SK, Kumar SK, Biswas J, Fogla R, Gopal L, Padmanabhan P. Self-induced corneal crystals: a case report. Cornea. May 2000;19(3):410-1. [Medline].

  13. Rauber A. Observations on the idioblasts of Dieffenbachia. J Toxicol Clin Toxicol. 1985;23(2-3):79-90. [Medline].

  14. Sanchez-Morillas L. Contact dermatitis due to Dieffenbachia. Contact Dermatitis. Sep 2005;53(3):172-3. [Medline].

  15. Seet B, Chan WK, Ang CL. Crystalline keratopathy from Dieffenbachia plant sap. Br J Ophthalmol. Jan 1995;79(1):98-9. [Medline].

Further Reading

Keywords

Caladium, Dieffenbachia, Philodendron, dumb cane, dumbcane, elephant's ears, plant poisoning, toxic plants, contact dermatitis, keratoconjunctivitis, aortoesophageal fistula, respiratory compromise

Contributor Information and Disclosures

Author

Jennifer S Boyle, MD, PharmD, Fellow in Toxicology, University of Virginia Health System
Disclosure: Nothing to disclose.

Coauthor(s)

Christopher P Holstege, MD, Associate Professor of Emergency Medicine and Pediatrics, University of Virginia; Director, Division of Medical Toxicology, Center of Clinical Toxicology; Medical Director, Blue Ridge Poison Ctr, Associate Medical Toxicology Fellowship Director, VA Dept of Health
Christopher P Holstege, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Association for the Advancement of Science, American College of Emergency Physicians, American College of Medical Toxicology, American Medical Association, Medical Society of Virginia, Society for Academic Emergency Medicine, Society of Toxicology, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Michael E Mullins, MD, Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine
Michael E Mullins, MD is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Emergency Physicians
Disclosure: Johnson & Johnson stock ownership None; Savient Pharmaceuticals stock ownership None

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Jeffrey R Tucker, MD, Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center
Jeffrey R Tucker, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Pediatrics, and Massachusetts Medical Society
Disclosure: Merck Salary Employment

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Timothy E Corden, MD, Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin
Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.